Catalyst Biosciences, Inc.

189 articles about Catalyst Biosciences, Inc.

• Catalyst Biosciences Receives Patent in the European Union for Its Factor IX PortfolioFIX patent including DalcA and CB 2679d-GT, now issued in all major markets

  4/28/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced the European Patent Office has issued the Company a FIX portfolio patent covering the lead clinical candidate, dalcinonacog alfa (DalcA) for Factor IX (FIX) replacement therapy, and the Company’s FIX preclinical gene therapy candidate, CB 2679d-GT. "This

• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

• Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)Final results to be presented during the second quarter

  4/21/2020

  Catalyst Biosciences, Inc., a biopharmaceutical company developing novel subcutaneous therapies for hemophilia and other bleeding disorders, announced completion of dosing and the 30-day follow-up period for its Phase 2b trial of SQ dalcinonacog alfa.

• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: April 8

  4/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.

• Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors

  4/6/2020

  Catalyst Biosciences, Inc. today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a pivotal Phase 3 trial design for Marzeptacog alfa (activated) – MarzAA. The open-label trial will evaluate the effi

• Catalyst Biosciences to Present at the Cowen Healthcare Conference

  2/24/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare Conference at 8:40 a.m. ET on Tuesday, March 3, 2020, in Boston.

• Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update

  2/20/2020

  Catalyst Biosciences, Inc., announced its operating and financial results for the fourth quarter and full-year ending December 31, 2019 and provided a corporate update.

• Catalyst Biosciences Announces Closing of Public Offering of Common Stock - Feb. 18, 2020

  2/18/2020

  Catalyst Biosciences, Inc. announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock.

• Catalyst Biosciences Announces Pricing of Public Offering of Common Stock - Feb. 13, 2020

  2/13/2020

  Catalyst Biosciences, Inc. announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public.

• Catalyst Biosciences Announces Proposed Public Offering of Common Stock - Feb. 12, 2020

  2/12/2020

  Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, announced that it is offering shares of its common stock in an underwritten public offering.

• 

  Clinical Catch-Up: February 3-7, 2020

  2/10/2020

  Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.

• Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress

  2/7/2020

  Enrollment in the DalcA trial is complete; results demonstrate DalcA provides Factor IX (FIX) activity exceeding the efficacy endpoint with no anti-drug antibodies

• Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

  1/27/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in The Hague, Netherlands on February 5 - 7, 2020.

• Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

  1/17/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. 

• Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

  12/19/2019

  Catalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tiered royalties up to low double digits

• Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

  12/9/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the 61st Annual American Society of Hematology (ASH) meeting held December 7-10, 2019 in Orlando, Florida.

• Catalyst Biosciences to Present at the Stifel Healthcare Conference

  11/12/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Stifel 2019 Healthcare Conference at 9:10 a.m. ET on Tuesday, November 19, 2019, in New York.

• Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update

  11/7/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2019 and provided a corporate update.

• Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference

  11/6/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s  subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 61st Annual American Society of Hematology (ASH) meeting being held December 7-10, 2019 in Orlando, Florida.